315 related articles for article (PubMed ID: 29262505)
1. [Discrimination and clinical value of plasma metabolomic profiles in multidrug resistant epithelial ovarian cancer].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):896-902. PubMed ID: 29262505
[No Abstract] [Full Text] [Related]
2. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
3. Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery.
Zhang F; Zhang Y; Ke C; Li A; Wang W; Yang K; Liu H; Xie H; Deng K; Zhao W; Yang C; Lou G; Hou Y; Li K
Metabolomics; 2018 Apr; 14(5):65. PubMed ID: 30830339
[TBL] [Abstract][Full Text] [Related]
4. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
5. Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer.
Xie H; Hou Y; Cheng J; Openkova MS; Xia B; Wang W; Li A; Yang K; Li J; Xu H; Yang C; Ma L; Li Z; Fan X; Li K; Lou G
Oncotarget; 2017 May; 8(19):32134-32146. PubMed ID: 28389631
[TBL] [Abstract][Full Text] [Related]
6. Saturated fatty acids as possible important metabolites for epithelial ovarian cancer based on the free and esterified fatty acid profiles determined by GC-MS analysis.
Yin R; Yang T; Su H; Ying L; Liu L; Sun C
Cancer Biomark; 2016 Sep; 17(3):259-269. PubMed ID: 27802202
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.
Han Y; Huang H; Xiao Z; Zhang W; Cao Y; Qu L; Shou C
PLoS One; 2012; 7(12):e52745. PubMed ID: 23300757
[TBL] [Abstract][Full Text] [Related]
8. Serum 27-nor-5β-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer.
Chen J; Zhang X; Cao R; Lu X; Zhao S; Fekete A; Huang Q; Schmitt-Kopplin P; Wang Y; Xu Z; Wan X; Wu X; Zhao N; Xu C; Xu G
J Proteome Res; 2011 May; 10(5):2625-32. PubMed ID: 21456628
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
10. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
Odunsi K; Wollman RM; Ambrosone CB; Hutson A; McCann SE; Tammela J; Geisler JP; Miller G; Sellers T; Cliby W; Qian F; Keitz B; Intengan M; Lele S; Alderfer JL
Int J Cancer; 2005 Feb; 113(5):782-8. PubMed ID: 15499633
[TBL] [Abstract][Full Text] [Related]
11. Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry.
Li J; Xie H; Li A; Cheng J; Yang K; Wang J; Wang W; Zhang F; Li Z; Dhillon HS; Openkova MS; Zhou X; Li K; Hou Y
Oncotarget; 2017 Jul; 8(29):46834-46845. PubMed ID: 27564116
[TBL] [Abstract][Full Text] [Related]
12. Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes.
Teng PN; Wang G; Hood BL; Conrads KA; Hamilton CA; Maxwell GL; Darcy KM; Conrads TP
Br J Cancer; 2014 Jan; 110(1):123-32. PubMed ID: 24178762
[TBL] [Abstract][Full Text] [Related]
13. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry.
Zhang T; Wu X; Yin M; Fan L; Zhang H; Zhao F; Zhang W; Ke C; Zhang G; Hou Y; Zhou X; Lou G; Li K
Clin Chim Acta; 2012 May; 413(9-10):861-8. PubMed ID: 22309680
[TBL] [Abstract][Full Text] [Related]
14. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform.
Fan L; Zhang W; Yin M; Zhang T; Wu X; Zhang H; Sun M; Li Z; Hou Y; Zhou X; Lou G; Li K
Acta Oncol; 2012 Apr; 51(4):473-9. PubMed ID: 22283470
[TBL] [Abstract][Full Text] [Related]
15. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
16. Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling.
Zhang H; Ge T; Cui X; Hou Y; Ke C; Yang M; Yang K; Wang J; Guo B; Zhang F; Lou G; Li K
Mol Biosyst; 2015 Feb; 11(2):516-21. PubMed ID: 25424060
[TBL] [Abstract][Full Text] [Related]
17. Large-scale profiling of metabolic dysregulation in ovarian cancer.
Ke C; Hou Y; Zhang H; Fan L; Ge T; Guo B; Zhang F; Yang K; Wang J; Lou G; Li K
Int J Cancer; 2015 Feb; 136(3):516-26. PubMed ID: 24895217
[TBL] [Abstract][Full Text] [Related]
18. Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.
Wu W; Wang Q; Yin F; Yang Z; Zhang W; Gabra H; Li L
Int J Oncol; 2016 Oct; 49(4):1651-65. PubMed ID: 27511453
[TBL] [Abstract][Full Text] [Related]
19. SPME-LC/MS-based serum metabolomic phenotyping for distinguishing ovarian cancer histologic subtypes: a pilot study.
Olkowicz M; Rosales-Solano H; Kulasingam V; Pawliszyn J
Sci Rep; 2021 Nov; 11(1):22428. PubMed ID: 34789766
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
